知镜 Cognispect · 医学文献与研究工作台

GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Diabetic Nephropathy: A Comparative Study .

Alghadeer SG, Kanfar SS, Algallaf ZD, Alfardan FM, Alshammrany R, Farhat M, Cyrus C.
Saudi medical journal · 2026-07-07 · PMID 42445750

文献摘要

Objective To investigate the effects of glucagon-like peptide-1 receptor agonist (GLP-1RAs) on renal function in type 2 diabetes mellitus (T2DM) patients and compared their efficacy to sodium-glucose co-transporter-2 inhibitors (SGLT-2i) in managing diabetic nephropathy. Methods This is a retrospective cohort study conducted at King Fahad University Hospital, including 115 adults (≥18 years) with T2DM and baseline estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m 2 , treated with GLP-1RAs or SGLT-2i for over 1 year. Patients on renal replacement therapy, nephrotoxic drugs, or with incomplete records were excluded. Data were analyzed with Jeffrey's Amazing Statistics Program; the significant value is p Results Participants were treated with either SGLT-2i (67.8%) or GLP-1RAs (32.2%). Both groups showed minimal improvements in glycemic control, hemoglobin A1c decreased from 7.86% to 7.66% (SGLT-2i) and from 8% to 7.76% (GLP-1RAs). Estimated GFR minimally improved by 0.5-1.2 mL/min/1.73m 2 (GLP-1RAs) and changed by -1.2 to +10.1 mL/min/1.73m 2 (SGLT-2i). Urine albumin/creatinine ratio dropped by 13.35 mg/g with GLP-1RAs but increased by 49.86 mg/g with SGLT-2i. Conclusions Both medications offered comparable glycemic and renal benefits. The GLP-1RAs, however, demonstrated more favorable effects on albuminuria, suggesting potential for superior renal protection in nascent diabetic nephropathy.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。